targeting inflammation using salsalate for type 2 diabetes-stage ii

Conditions: Type 2 Diabetes Mellitus

Summary: growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. in this study we will determine whether salsalate, a member of the commonly used non-steroidal anti-inflammatory drug (nsaid) class, is effective in lowering sugars in patients with type 2 diabetes. the study will determine whether salicylates represent a new pharmacological option for diabetes management. the study is conducted in two stages. enrollment in the first stage is complete. the primary objective of the first stage was to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. the primary objective of stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (t2d); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk.


Eligibility criteria:
inclusion criteria: 1. type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin secretagogue (including sfu, non-sfu, and dipeptidyl peptidase iv (dpp-4) inhibitors), alpha-glucosidase inhibitors, or bile acid sequestrants (dosed once per day such that study drug can be administered ≥ 4 hours prior to sequestrant); or a combination of up to two of these at maximal dose. dosing must be stable for 8 weeks prior to screening. participant must have been diagnosed with t2d at least 8 weeks before screening. 2. fpg ≤ 225 mg/dl and hba1c≥7% and ≤ 9.5% at screening. 3. age ≥18 and \<75 4. women of childbearing potential agree to use an appropriate contraceptive method (hormonal, iud, or diaphragm) exclusion criteria: 1. no prior participation in stage i of tinsal-t2d ; exception: a participant who failed screening for hba1c in stage i will be allowed to re-screen for stage ii. 2. type 1 diabetes and/or history of ketoacidosis determined by medical history 3. history of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation 4. history of long-term therapy with insulin (\>30 days) within the last year 5. therapy with rosiglitazone (avandia) or pioglitazone (actos), alone or in combination in the previous 6 months; or exendin-4 (byetta), alone or in combination in the previous 3 months 6. pregnancy or lactation 7. patients requiring oral corticosteroids within 3 months or recurrent continuous oral corticosteroid treatment (more than 2 weeks) 8. use of weight loss drugs \[e.g., xenical (orlistat), meridia (sibutramine), acutrim (phenylpropanol-amine), or similar over-the-counter medications\] within 3 months of screening or intentional weight loss of ≥ 10 lbs in the previous 6 months 9. surgery within 30 days prior to screening 10. serum creatinine \>1.4 for women and \>1.5 for men or egfr \<60 \[possible chronic kidney disease stage 3 or greater calculated using the modification of diet in renal disease (mdrd) equation 11. history of chronic liver disease including hepatitis b or c 12. history of peptic ulcer or endoscopy demonstrated gastritis 13. history of acquired immune deficiency syndrome or human immunodeficiency virus (hiv) 14. history of malignancy, except participants who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma 15. new york heart association class iii or iv cardiac status or hospitalization for congestive heart failure 16. history of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months 17. uncontrolled hypertension (defined as systolic blood pressure \>150 mmhg or diastolic blood pressure \>95 mmhg on three or more assessments on more than one day). if on blood pressure medications, dosing should be stable for 2 weeks prior to randomization. 18. history of drug or alcohol abuse, or current weekly alcohol consumption \>10 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed dccktail containing 1 ounce of alcohol) 19. hemoglobin \<12 g/dl (males), \<10 g/dl (females) at screening\* 20. platelets \<100,000 cu mm at screening 21. ast (sgot) \>2.50 x uln or alt (sgpt) \>2.50 x uln at screening 22. total bilirubin \>1.50 x uln at screening 23. triglycerides (tg) \>500 mg/dl at screening 24. poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study 25. previous allergy to aspirin 26. chronic or continuous use (daily for more than 7 days) of nonsteroidal anti-inflammatory drugs within the preceding 2 months 27. use of warfarin (coumadin), clopidogrel (plavix), dipyridamole (persantine), heparin or other anticoagulants 28. use of probenecid (benemid, probalan), sulfinpyrazone (anturane) or other uricosuric agents 29. macroalbuminuria, defined as spot urine protein \>300 mcg/mg cr at screening 30. pre-existing chronic tinnitus

Keywords: type 2 diabetes mellitus (t2d) inflammation obesity metabolic syndrome salicylates